Jerel Davis

Dr. Davis brings a distinguished track record as an investor and advisor to his role as a board member of Graphite Bio, with proven expertise in company creation, R&D alliances, and corporate partnerships. He currently serves as managing director of Versant Ventures. During his nine-year tenure at Versant, Dr. Davis has helped propel the growth strategies of a multitude of the firm’s portfolio companies including BlueRock Therapeutics, CRISPR Therapeutics, Repare Therapeutics, Chinook Therapeutics, Tentarix Biotherapeutics, Turnstone Biologics, Ventus Therapeutics, and several others. Prior to joining Versant, Dr. Davis was an associate principal at McKinsey & Company, where he advised a broad range of pharmaceutical, biotechnology, medical device, and molecular diagnostics companies. He has worked in a number of healthcare markets globally including the U.S., Canada, Europe, China, Russia, and India.